Alberto S Tresoldi1, Laura F Sburlati1, Marcello Rodari2, Mink S Schinkelshoek3, Michela Perrino4,5, Simone De Leo4,5, Laura Montefusco6,4, Paolo Colombo1, Maura Arosio6,4, Andrea Gerardo Antonio Lania1,7, Laura Fugazzola4,5, Arturo Chiti8. 1. Unit of Endocrinology, Humanitas Research Hospital, Rozzano, MI, Italy. 2. Nuclear Medicine Department, Humanitas Research Hospital, Via A. Manzoni 56, 20089, Rozzano, MI, Italy. 3. Leyden University, Leiden, The Netherlands. 4. Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. 5. Endocrine Unit, Fondazione IRCCS Ca' Granda, Milan, Italy. 6. Unit of Endocrine Diseases and Diabetology, Ospedale San Giuseppe Multimedica, Milan, Italy. 7. Department of Biotechnologies and Translational Medicine, University of Milan, Milan, Italy. 8. Nuclear Medicine Department, Humanitas Research Hospital, Via A. Manzoni 56, 20089, Rozzano, MI, Italy. arturo.chiti@humanitas.it.
Abstract
PURPOSE: The aim of this study was to evaluate the efficacy of post-operative radioiodine ablation with 1,850 MBq after recombinant human thyrotropin (rhTSH) administration in patients with differentiated thyroid carcinoma (DTC). We also aimed to assess the prognostic role of several patient features on the outcome of ablation. METHODS: We retrospectively analyzed data from a total of 125 patients with DTC who underwent post-operative radioiodine ablation with 1,850 MBq of ¹³¹I after preparation with rhTSH. One injection of 0.9 mg rhTSH was administered on each of two consecutive days; ¹³¹I therapy was delivered 24 h after the last injection, followed by a post-therapy whole-body scan. Successful ablation was assessed 6-12 months later and defined as an rhTSH-stimulated serum thyroglobulin (Tg) level ≤1.0 ng/ml and a normal neck ultrasound. RESULTS: Patients were stratified according to the American Thyroid Association (ATA) Management Guidelines for Differentiated Thyroid Cancer. Successful ablation was achieved in 82.4 % of patients, with an ablation rate of 95.1 % in low-risk patients and 76.2 % in intermediate-risk patients. Analyzing the correlation between ablation outcome and patient characteristics, we found a statistically significant association between failure to ablate and class of risk based on ATA guidelines (p = 0.025) and a stimulated Tg value at ablation of above 5 ng/ml (p < 0.001). CONCLUSION: The use of 1,850 MBq post-operative radioiodine thyroid remnant ablation in association with rhTSH is effective for low- and intermediate-risk patients. Moreover, in our study, we found a statistical correlation between failure to ablate and class of risk based on ATA guidelines for DTC and a stimulated Tg value at ablation.
PURPOSE: The aim of this study was to evaluate the efficacy of post-operative radioiodine ablation with 1,850 MBq after recombinant human thyrotropin (rhTSH) administration in patients with differentiated thyroid carcinoma (DTC). We also aimed to assess the prognostic role of several patient features on the outcome of ablation. METHODS: We retrospectively analyzed data from a total of 125 patients with DTC who underwent post-operative radioiodine ablation with 1,850 MBq of ¹³¹I after preparation with rhTSH. One injection of 0.9 mg rhTSH was administered on each of two consecutive days; ¹³¹I therapy was delivered 24 h after the last injection, followed by a post-therapy whole-body scan. Successful ablation was assessed 6-12 months later and defined as an rhTSH-stimulated serum thyroglobulin (Tg) level ≤1.0 ng/ml and a normal neck ultrasound. RESULTS:Patients were stratified according to the American Thyroid Association (ATA) Management Guidelines for Differentiated Thyroid Cancer. Successful ablation was achieved in 82.4 % of patients, with an ablation rate of 95.1 % in low-risk patients and 76.2 % in intermediate-risk patients. Analyzing the correlation between ablation outcome and patient characteristics, we found a statistically significant association between failure to ablate and class of risk based on ATA guidelines (p = 0.025) and a stimulated Tg value at ablation of above 5 ng/ml (p < 0.001). CONCLUSION: The use of 1,850 MBq post-operative radioiodine thyroid remnant ablation in association with rhTSH is effective for low- and intermediate-risk patients. Moreover, in our study, we found a statistical correlation between failure to ablate and class of risk based on ATA guidelines for DTC and a stimulated Tg value at ablation.
Authors: Richard T Kloos; Vani Duvuuri; Sissy M Jhiang; Kenneth V Cahill; Jill A Foster; John A Burns Journal: J Clin Endocrinol Metab Date: 2002-12 Impact factor: 5.958
Authors: Pamela R Schroeder; Bryan R Haugen; Furio Pacini; Christoph Reiners; Martin Schlumberger; Steven I Sherman; David S Cooper; Kathryn G Schuff; Lewis E Braverman; Monica C Skarulis; Terry F Davies; Ernest L Mazzaferri; Gilbert H Daniels; Douglas S Ross; Markus Luster; Mary H Samuels; Bruce D Weintraub; E Chester Ridgway; Paul W Ladenson Journal: J Clin Endocrinol Metab Date: 2006-01-04 Impact factor: 5.958
Authors: Ujjal Mallick; Clive Harmer; Beng Yap; Jonathan Wadsley; Susan Clarke; Laura Moss; Alice Nicol; Penelope M Clark; Kate Farnell; Ralph McCready; James Smellie; Jayne A Franklyn; Rhys John; Christopher M Nutting; Kate Newbold; Catherine Lemon; Georgina Gerrard; Abdel Abdel-Hamid; John Hardman; Elena Macias; Tom Roques; Stephen Whitaker; Rengarajan Vijayan; Pablo Alvarez; Sandy Beare; Sharon Forsyth; Latha Kadalayil; Allan Hackshaw Journal: N Engl J Med Date: 2012-05-03 Impact factor: 91.245
Authors: Heribert Hänscheid; Michael Lassmann; Markus Luster; Stephen R Thomas; Furio Pacini; Claudia Ceccarelli; Paul W Ladenson; Richard L Wahl; Martin Schlumberger; Marcel Ricard; Al Driedger; Richard T Kloos; Steven I Sherman; Bryan R Haugen; Vincent Carriere; Carine Corone; Christoph Reiners Journal: J Nucl Med Date: 2006-04 Impact factor: 10.057
Authors: H R Maxon; S R Thomas; V S Hertzberg; J G Kereiakes; I W Chen; M I Sperling; E L Saenger Journal: N Engl J Med Date: 1983-10-20 Impact factor: 91.245